Summarized by Masters of Longevity from Nature - Biotechnology.
Clinical and preclinical work shows poor heart muscle transduction with AAV delivery.
Key Takeaways
- Human trials reported less than one percent cardiomyocyte uptake.
- Delivery method was shown to strongly affect vector distribution.
- Improved administration has not established clinical efficacy alone.
